SQZ Biotechnologies is a biotechnology company developing cell therapies for patients with cancer and other serious conditions. In oncology, Co. is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Co.'s product candidate pipeline includes: SQZ® Enhanced Antigen Presenting Cell Platform, which is designed to generate tumor-specific CD8+ T cell activation to drive the antitumor immune response; and SQZ® Activating Antigen Carrier Platform, which is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells with tumor-specific antigens and adjuvant. The SQZ average annual return since 2020 is shown above.
The Average Annual Return on the SQZ average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SQZ average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SQZ average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|